Xtant Medical (NYSEAMERICAN:XTNT) Share Price Crosses Above Two Hundred Day Moving Average – Should You Sell?

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) shares passed above its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.68 and traded as high as $0.72. Xtant Medical shares last traded at $0.6820, with a volume of 135,680 shares trading hands.

Analyst Ratings Changes

Separately, BTIG Research decreased their price target on Xtant Medical from $2.00 to $1.50 and set a “buy” rating on the stock in a report on Tuesday, November 11th. One equities research analyst has rated the stock with a Buy rating, According to MarketBeat, the stock has a consensus rating of “Buy” and a consensus price target of $1.50.

Xtant Medical Trading Down 2.5%

The company has a quick ratio of 1.06, a current ratio of 2.21 and a debt-to-equity ratio of 0.35. The company has a market capitalization of $95.48 million, a P/E ratio of 68.27 and a beta of -0.08. The firm’s 50-day moving average price is $0.71 and its 200 day moving average price is $0.68.

Xtant Medical (NYSEAMERICAN:XTNT) last released its quarterly earnings results on Monday, November 10th. The medical device company reported $0.01 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.01) by $0.02. The business had revenue of $27.77 million during the quarter, compared to the consensus estimate of $32.70 million. Xtant Medical had a return on equity of 3.77% and a net margin of 1.32%.

Hedge Funds Weigh In On Xtant Medical

Large investors have recently bought and sold shares of the stock. Jane Street Group LLC purchased a new position in Xtant Medical during the 2nd quarter worth $26,000. Mink Brook Asset Management LLC lifted its position in shares of Xtant Medical by 125.8% during the second quarter. Mink Brook Asset Management LLC now owns 109,466 shares of the medical device company’s stock valued at $81,000 after purchasing an additional 60,997 shares in the last quarter. Crescent Grove Advisors LLC boosted its holdings in Xtant Medical by 94.3% during the second quarter. Crescent Grove Advisors LLC now owns 412,024 shares of the medical device company’s stock worth $304,000 after purchasing an additional 200,000 shares during the last quarter. Vanguard Group Inc. grew its position in Xtant Medical by 4.6% in the 3rd quarter. Vanguard Group Inc. now owns 2,355,671 shares of the medical device company’s stock worth $1,529,000 after purchasing an additional 104,159 shares in the last quarter. Finally, AWM Investment Company Inc. purchased a new stake in Xtant Medical in the 2nd quarter valued at about $4,875,000. 69.33% of the stock is currently owned by institutional investors.

Xtant Medical Company Profile

Xtant Medical, Inc is a medical technology company focused on the development, manufacturing and distribution of bone graft, spine biologics and related implantable medical devices. The company’s product portfolio is designed to address critical needs in spinal fusion, orthopedics and trauma surgery by providing a range of solutions that promote bone growth, structural support and patient recovery.

The company’s offerings include an array of bone graft substitutes – such as demineralized bone matrix putties and fibers – interbody fusion devices, spinal fixation systems and biologic agents.